张素林

张素林 博士

研究员，国科大杭州高等研究院

浙江省杭州市西湖区象山支路1号 310012

E-mail: slzhang@simm.ac.cn

教育背景：

（1）2014.9 ~ 2018.7，复旦大学 博士

（2）2011.9 ~ 2014.7，浙江工业大学 硕士

（3）2007.9 ~ 2011.7，安徽农业大学 本科

工作经历：

（1）2026.03~至今，国科大杭州高等研究院药学院，研究员

（2）2025.10~至今，中国科学院上海药物研究所，研究员

（3）2020.10~2025.10，中国科学院上海药物研究所，副研究员

（4）2020.09~2020.10，中国科学院上海药物研究所，助理研究员

（5）2018.07~2020.09，中国科学院上海药物研究所，博士后

研究方向：

主要从事基于人工智能（AI）的药理学研究，围绕AI与药理学交叉创新，开展三个层次的研究工作：一是面向药理学科学问题，与团队成员合作开展AI算法的开发与应用研究；二是构建湿实验数据反哺AI算法优化的迭代体系，开展干湿融合、双向赋能的闭环研究；三是干实验启发湿实验，开展AI算法引领的新药理学和新药物研发方向的探索。

代表性研究成果：

围绕上述研究体系，近年来以通讯或一作（含共同）身份在Sci Transl Med、Nat Chem Biol、Nat Cancer、Nat Immunol、Nat Commun、Cell Genom、Protein Cell、Adv Sci、Acta Pharm Sin B、Sci China Life Sci、Acta Pharmacol Sin、J Med Chem等期刊上已发表或已被接收研究性论文40余篇；申请发明专利30项，其中PCT 8项，已获授权4项。

(1) Jie Yu#, Xia Sheng#, Zhehuan Fan#, Zhaokun Wang#, Duanhua Cao#, Yufan Tang, Yongxin Hao, Yingying Zhang, Panpan Shao, Huicong Ma, Tian Cao, Chuanlong Zeng, JingXin Rao, Mingan Chen, Kaixian Chen, Xutong Li, Dan Teng, Xiaomin Luo, Mingliang Wang*, Sulin Zhang*, Mingyue Zheng*. Atomic-Level Protein–Ligand Recognition with PBCNet2.0 for Probe Discovery. Nat Chem Biol. 2026, Accept.

(2) Shu-Qing Chu#, Yi-Jie Chen#, Rui-Rui Yang#, Dan Teng, Gui-Zhen Zhou, Ying-Ying Zhang, Bu-Ying Niu, Jia-Hang Xu, Ke-Xin Lin, Xin-Yu Yang, Xu-Tong Li, Ming-Yue Zheng*, Su-Lin Zhang*. Discovery and characterization of a novel HIF-2α agonist for the treatment of CKD-related renal anemia. Acta Pharmacol Sin. 2026;47(2):504-517.

(3) Ruirui Yang#, Bei Wang#, Zhaoming Su, Ying Song, Yingying Zhang, Yadan Liu, Yinghui Zhang, Changyu He, Xi Yang, Feisheng Zhong, Zunyun Fu, Yiluan Ding, Naixia Zhang, Rui Li, Shuqing Chu, Chuanhai Xu, Jian Sun, Haiwei Shen, Wei Geng*, Sulin Zhang*, Mingyue Zheng*. Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy. Sci Transl Med. 2025;17(801):eadn6921.

(4) Yadan Liu#, Jialin Ye#, Zisheng Fan#, Xiaolong Wu#, Yinghui Zhang#, Ruirui Yang, Bing Jiang, Yajie Wang, Min Wu, Jingyi Zhou, Jingyi Meng, Zhiming Ge, Guizhen Zhou, Yuan Zhu, Yichuan Xiao*, Mingyue Zheng*, Sulin Zhang*. Ginkgetin Alleviates Inflammation and Senescence by Targeting STING. Adv Sci. 2025;12(2):e2407222.

(5) Hanling Wang#, Sulin Zhang#, Qiang Pan#, Jiacheng Guo, Ni Li, Lifan Chen, Junyu Xu, Jingyi Zhou, Yongqiang Gu, Xuege Wang, Guoying Zhang, Yannan Lian, Wei Zhang, Naiheng Lin, Zige Jin, Yi Zang, Weihua Lan, Xiaoyan Cheng, Minjia Tan, Fei Xavier Chen, Jun Jiang, Qiuli Liu*, Mingyue Zheng*, Jun Qin*. Targeting ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation. Nat Cancer. 2025;6(4):629-646.

(6) Hui Houa#, Jingyi Zhou#, Qibang Sui#, Changfa Zhang, Zhaoming Su, Rongrong Cui, Bin Shan, Peijia Xu, Zhengyang Chen, Bing Jiang, Manjia Li, Keke Zhang, Yajie Wang, Ning Ma, Dan Teng*, Mingyue Zheng*, Sulin Zhang*. Discovery of 3-(fluoro-imidazolyl) pyridazine Derivatives as Potent STING Agonists with Antitumor Activity. J Med Chem. 2025;68(10):9864-9885.

(7) Xiaochu Tong, Ning Qu, Xiangtai Kong, Shengkun Ni, Jingyi Zhou, Kun Wang, Lehan Zhang, Yiming Wen, Jiangshan Shi, Sulin Zhang*, Xutong Li*, Mingyue Zheng*. Deep representation learning of chemical-induced transcriptional profile for phenotype-based drug discovery. Nat Commun. 2024;15(1):5378.

(8) Xuehui Long#, Sulin Zhang#, Yuliang Wang#, Jingjing Chen#, Yanlai Lu#, Hui Hou#, Bichun Lin#, Xutong Li, Chang Shen, Ruirui Yang, Huamin Zhu, Rongrong Cui, Duanhua Cao, Geng Chen, Dan Wang, Yun Chen, Sulan Zhai, Zhiqin Zeng, Shusheng Wu, Mengting Lou, Junhong Chen, Jian Zou, Mingyue Zheng*, Jun Qin*, Xiaoming Wang*. Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity. Nat Immunol. 2024;25(3):525-536.

(9) Shengkun Ni#, Xiangtai Kong#, Yingying Zhang#, Zhengyang Chen#, Zhaokun Wang, Zunyun Fu, Ruifeng Huo, Xiaochu Tong, Ning Qu, Xiaolong Wu, Kun Wang, Wei Zhang, Runze Zhang, Zimei Zhang, Jiangshan Shi, Yitian Wang, Ruirui Yang, Xutong Li*, Sulin Zhang*, Mingyue Zheng*. Identifying compound-protein interactions with knowledge graph embedding of perturbation transcriptomics. Cell Genom. 2024;4(10):100655.

(10) Yinghui Zhang#, Yadan Liu#, Bing Jiang#, Lifan Chen, Jie Hu, Buying Niu, Jie Chang, Zisheng Fan, Jingyi Zhou, Yajie Wang, Dan Teng, Ning Ma, Xiaofeng Wang, Ruirui Yang*, Mingyue Zheng*, Sulin Zhang*. Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases. Sci China Life Sci. 2024;67(12):2664-2677.

(11) Lifan Chen#, Zisheng Fan#, Jie Chang#, Ruirui Yang#, Hui Hou#, Hao Guo, Yinghui Zhang, Tianbiao Yang, Chenmao Zhou, Qibang Sui, Zhengyang Chen, Chen Zheng, Xinyue Hao, Keke Zhang, Rongrong Cui, Zehong Zhang, Hudson Ma, Yiluan Ding, Naixia Zhang, Xiaojie Lu, Xiaomin Luo, Hualiang Jiang, Sulin Zhang*, Mingyue Zheng*. Sequence-based drug design as a concept in computational drug design. Nat Commun. 2023;14(1):4217.

(12) Zehui Zhou#, Guizhen Zhou#, Chuan Zhou#, Zisheng Fan, Rongrong Cui, Yupeng Li, Rui Li, Yuejiao Gu, Huajie Li, Zhiming Ge, Xiaojia Cai, Bing Jiang, Dan Wang, Mingyue Zheng*, Tianfeng Xu*, Sulin Zhang*. Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers. J Med Chem. 2023;66(6):4197-4214.

(13) Jing-Yi Zhou#, Rui-Rui Yang#, Jie Chang, Jia Song, Zi-Sheng Fan, Ying-Hui Zhang, Cheng-Hao Lu, Hua-Liang Jiang*, Ming-Yue Zheng*, Su-Lin Zhang*. Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain. Acta Pharmacol Sin. 2023;44(2):475-485.

(14) Feisheng Zhong#, Xiaolong Wu#, Ruirui Yang#, Xutong Li, Dingyan Wang, Zunyun Fu, Xiaohong Liu, XiaoZhe Wan, Tianbiao Yang, Zisheng Fan, Yinghui Zhang, Xiaomin Luo, Kaixian Chen, Sulin Zhang*, Hualiang Jiang*, Mingyue Zheng*. Drug target inference by mining transcriptional data using a novel graph convolutional network framework. Protein Cell. 2022;13(4):281-301.

(15) Jie Chang#, Ruirui Yang#, Lifan Chen#, Zisheng Fan, Jingyi Zhou, Hao Guo, Yinghui Zhang, Yadan Liu, Guizhen Zhou, Keke Zhang, Kaixian Chen, Hualiang Jiang*, Mingyue Zheng*, Sulin Zhang*. Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer. Acta Pharm Sin B. 2022;12(5):2619-2622.

科研项目：

（1）2025.01 ~ 2028.12，国家自然科学基金面上项目，主持

（2）2025.02 ~ 2030.01，中国科学院基础与交叉前沿科研先导专项课题，主持

（3）2023.01 ~ 2026.12，中国科学院青年创新促进会会员项目，主持

（4）2022.04 ~ 2025.03，上海市自然科学基金面上项目，主持

（5）2022.01 ~ 2024.12，临港实验室求索杰出青年计划开放课题项目，主持

（6）2020.09 ~ 2022.09，中国博士后科学基金特别资助项目，主持

（7）2020.01 ~ 2022.12，国家自然科学基金青年科学基金项目，主持

（8）2019.05 ~ 2022.04，上海市科委青年科技英才扬帆计划项目，主持

（9）2018.12 ~ 2021.12，中国博士后科学基金面上项目，主持

（10）2018.12 ~ 2020.09，上海市超级博士后激励计划项目，主持